AI picks who gets a second chance at targeted breast cancer therapy

NCT ID NCT07227233

Recruiting now Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

First seen Nov 12, 2025 · Last updated May 21, 2026 · Updated 23 times

Summary

This study tests whether an artificial intelligence model can identify patients with advanced HR+ HER2- breast cancer whose tumors might still respond to a second CDK4/6 inhibitor after the first stopped working. About 105 participants will either receive the AI-recommended drug combination or standard care chosen by their doctor. The goal is to see if the AI-guided approach delays tumor growth and is safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of California, San Diego
RECRUITING

La Jolla, California, 92093, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BREAST CANCER